Medicus Pharma Ltd (NASDAQ:MDCX) Short Interest Update

Medicus Pharma Ltd (NASDAQ:MDCX) was the target of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totaling 1,045,598 shares, a decrease of 45.8% from the June 15th total of 1,928,591 shares. Based on an average trading volume of 2,653,037 shares, the days-to-cover ratio is presently 0.4 days. Currently, 2.0% of the company’s shares are sold short.

Analyst Ratings Changes

A number of brokerages recently commented on MDCX. Roth Capital assumed coverage on Medicus Pharma in a research report on Tuesday, April 21st. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a research report on Wednesday, July 8th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Medicus Pharma in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Medicus Pharma currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Hedge Funds Weigh In On Medicus Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MDCX. Jane Street Group LLC acquired a new position in shares of Medicus Pharma during the 2nd quarter worth about $41,000. Osaic Holdings Inc. increased its stake in shares of Medicus Pharma by 180.0% in the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after acquiring an additional 9,000 shares during the last quarter. Private Advisor Group LLC raised its position in shares of Medicus Pharma by 3.8% in the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after acquiring an additional 5,500 shares during the period. Yorkville Advisors Global LP acquired a new stake in shares of Medicus Pharma in the 3rd quarter valued at approximately $532,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Medicus Pharma during the 3rd quarter worth approximately $59,000.

Medicus Pharma Price Performance

Shares of Medicus Pharma stock traded up $0.06 on Thursday, hitting $0.41. 3,286,762 shares of the company’s stock traded hands, compared to its average volume of 3,755,537. The firm’s 50-day moving average price is $0.37 and its two-hundred day moving average price is $0.71. The stock has a market capitalization of $23.00 million, a PE ratio of -0.15 and a beta of -0.05. Medicus Pharma has a one year low of $0.25 and a one year high of $3.35.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.13). On average, analysts forecast that Medicus Pharma will post -0.51 earnings per share for the current fiscal year.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.